Glenmark gets USFDA nod for oral contraceptive pills
- David Headley pardoned, accepted as approver in 26/11 case on conditions
- Salman Khan acquitted of all charges in 2002 hit-and-run case
- Islamic State finance chief Abu Saleh killed in air strike: US
- Salman Khan thanks fans, says 'accept the decision with humility'
- Rajya Sabha washed out for third day over National Herald case
Drug firm Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic contraceptive norgestimate and ethinyl estradiol tablets.
Glenmark Generics Inc, a subsidiary of Glenmark Generics has been granted final approval for their abbreviated new drug application (ANDA) by the US Food and Drug Administration (USFDA) for Norgestimate and Ethinyl Estradiol tablets in the strengths of 0.25 mg/0.035 mg, Glenmark Pharmaceuticals said in a statement.
The tablets are generic version of Janssen Pharmaceuticals Inc oral contraceptive Ortho Cyclen tablets.
Citing IMS Health data for the 12-month period ending December 2011, the company said norgestimate and ethinyl estradiol tablets of strength 0.25 mg/0.035 mg garnered total market sales of approximately USD 88 million.
The company currently has 79 generic products authorised for distribution in the US market and 39 ANDA's pending approval with the USFDA, Glenmark said.
Today's approval is Glenmark's tenth female hormonal product authorised for distribution by the USFDA, it added.
Shares of Glenmark Pharmaceuticals were today trading at Rs 307.40 in the morning trade on BSE, down 0.47 per cent from its previous close.
- As they reimagine the international role of India and Japan, Modi and Abe are drawn together
- Why post-mortems of this year’s most crucial election are missing the point
- Voters are changing politics. Politicians must reform the civil services
- Pakistan: ‘Double Shahs’ profit from religious Muslims’ alienation from modern banking.
- Bhagwat’s acknowledgement of Babasaheb’s greatness is belated and hypocritical
- Government must ensure the disabilities law reaches out to the most needy